PARS2 and cancer: Daewoong Pharmaceutical Co. unveiled heterocyclic compounds to inhibit abnormal human prolyl-tRNA synthetase (ProRS) activity for the treatment of cancers, inflammatory diseases, autoimmune diseases, and fibrosis [59].